Over the last few years, the UK and EU competition authorities have continued to closely scrutinise the life sciences sector, investigating numerous different anticompetitive practices – including excessive pricing, illegal information exchange and market sharing arrangements, sometimes resulting in the disqualification of directors. There has been continued scrutiny of pay for delay agreements, leading to the issue of substantial fines, as well as a focus on mergers in this sector resulting in high-profile prohibitions by the authorities and abandonments of deals by the parties. In this article, we summarise some of the key antitrust developments in the sector under UK and EU competition law.
Click here to read more